Cover Image
市場調查報告書

全球搭配診斷(CDx)市場 - 產業分析與市場預測(2017年∼2022年)

Global Companion Diagnostics Market - Segmented by Technology, Indication and Geography - Growth, Trend and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 390597
出版日期 內容資訊 英文 112 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球搭配診斷(CDx)市場 - 產業分析與市場預測(2017年∼2022年) Global Companion Diagnostics Market - Segmented by Technology, Indication and Geography - Growth, Trend and Forecast (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 112 Pages
簡介

全球搭配診斷(CDx)市場,2014年價值45億美元,至2020年預計以35%的年複合成長率成長到270億美元。

本報告提供全球搭配診斷(CDx)市場相關調查,市場概要,各指標、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 報告的說明
  • 調查方法

第2章 搭配診斷市場概要

  • 簡介
    • 情境和背景
    • 體外診斷和搭配診斷的差異
    • 標籤相關考慮事項
    • 傳統的藥品&體外診斷的發展
    • 法律規範

第3章 全球搭配診斷市場趨勢

  • 市場成長要素
    • 新藥和診斷企業的成長
    • 癌症發病率的上升
    • 藥物的安全性/有效性概況的改善
    • 藥物開發成本的增加
    • 藥品核准流程的加速
  • 市場阻礙因素
    • 複雜的臨床試驗的實施
    • 智慧財產權的問題
    • 償付制度的問題
  • 市場機會
    • 研究投資
    • 新藥的突破
    • 更短的開發時間軸
    • 市場滲透的進展

第4章 全球搭配診斷市場:各指標

  • 市場概要
  • 肺癌
  • 乳癌
  • 大腸癌
  • 黑色素瘤
  • 白血病
  • 其他(腦瘤、胃癌、前列腺癌)

第5章 全球搭配診斷市場:各地區

  • 市場概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 市場佔有率分析

  • 主要企業的市場佔有率
  • 各市場區隔的主要企業

第7章 競爭情形

  • 新產品的創新
  • 協定,合作,合資企業,聯盟
  • 合併和收購
  • 法規機關

第8章 企業簡介

  • A&G Pharmaceutical, Inc.
  • Abbott Diagnostics
  • Biocrates Life Sciences AG
  • Clovis Oncology, Inc.
  • Dako A/S
  • EKF Diagnostics Holdings plc.
  • Eli Lilly and Company
  • Eutropics Pharmaceuticals, Inc.
  • Daan Diagnostics Ltd.
  • Foundation Medicine, Inc.
  • Genentech, Inc.
  • Intezyne, Inc.
  • Leica Biosystems GmbH
  • Myriad Genetics, Inc.
  • NEOMICS Co., Ltd.
  • NuCana Biomed Limited
  • Oxford Biodynamics Limited
  • Qiagen NV
  • Roche Diagnostics Limited
  • Siemens Healthcare Diagnostics Inc.
  • Skuldtech France
  • 武田藥品工業
  • TheraDiag SA
  • Thermo Fisher Scientific Inc.
  • Tocagen Inc.
  • Ventana Medical Systems, Inc.

第9章 附錄

  • 簡稱
  • 參考資料
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1893

The global companion diagnostics market has been estimated at USD 5.8 billion in 2017. The market is expected to register a CAGR of 22.7% during the forecast period, 2018 to 2023. North America accounted for the largest market share, accounting for approximately 35% of the global market share in 2017, while Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Personalized Medicines Accelerating Market Demand

One of the major factors driving the growth of the companion diagnostic market is the increasing demand for personalized medicines and awareness for the same, among the population. The rising cases of adverse drug reactions related to the drugs due to the lack of efficacy drive the need for companion diagnostics. With companies increasing their collaborations for better biomarkers and diagnostics to focus on cost regulations, there has been a significant number of opportunities of its applications in indications other than cancer, like cardiovascular, neurological, etc. The high rise in the capital is the basis for the prosperous future of this market.

High Cost of Therapeutics Development

One of the major hurdles restraining this market includes high cost involved in the development of therapeutics and diagnostic tests. With the high risk of failure in clinical trials, many companies prefer collaborations, to minimize their failure rate but co-development is also expected to be highly expensive. So for many individual manufacturers, this markets looks like a high-risk investment market. Apart from this, several diagnostic companies feel uncertain over an eventual agreement on the reimbursement status. All these factors restrict this market's growth globally.

North America Dominates this Market

The global market for companion diagnostics is segmented based on technology type, by indication and geographical regions. By geography, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America accounted for the largest market share, accounting for approximately 35% of the global market share in 2017. The efficacy of several drugs range between 30-75% and there have rising cases of side effects related to therapeutics such as Vioxx and Avandia, which has prompted the people for alternatives and raised their awareness regarding the benefits of personalized medicine driving this market. Apart from this, Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Recent Key Developments in the Market

January 2018: Myriad Genetics received FDA approval for BRACAnalysis CDx as Companion Diagnostic for Lynparza (olaparib).

January 2018: A new companion diagnostics agreement between Biocartis Group and Amgen was signed for the development of Idylla(TM) CDx biomarker tests used in the treatment of certain solid tumors.

December 2017: HTG Molecular Diagnostics signed master collaboration with Merck KGaA complementing companion diagnostics agreement for biomarker research program.

Major Key players: ABBOTT LABORATORIES, DAKO (AGILENT TECHNOLOGIES), ROCHE HOLDINGS, QIAGEN nv, SEIMENS HELTHINEERS, TAKEDA PHARMACEUTICALS, MYRIAD GENETICS, THERMO FISHER SCIENTIFIC, TACOGEN and ILLUMINA inc

Reasons to Purchase This Report

Current and future global companion diagnostics market outlook in the developed and emerging markets

Analyzing various perspectives of the market with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porters Five Forces
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threats of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
    • 6.1.2 Increasing Cases of Adverse Drug Reactions
    • 6.1.3 Co-Development of Drug and Diagnostic Technology
  • 6.2 Market Restraints
    • 6.2.1 High Cost Of Drug Development and Associated Clinical Trials
    • 6.2.2 Reimbursement Issues among Many Countries

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Immunohistochemistry (Ihc)
    • 7.1.2 Polymerase Chain Reaction (Pcr)
    • 7.1.3 In Situ Hybridization (Ish)
    • 7.1.4 Real-Time Pcr (Rt-Pcr)
    • 7.1.5 Gene Sequencing
    • 7.1.6 Others
  • 7.2 By Indication
    • 7.2.1 Lung Cancer
    • 7.2.2 Breast Cancer
    • 7.2.3 Coloractal Cancer
    • 7.2.4 Leukemia
    • 7.2.5 Melanoma
    • 7.2.6 Others
  • 7.3 Segmentation by Geography
    • 7.3.1 North America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East and Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of Middle East and Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers and Acquisition Analysis
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbott Laboratories
  • 9.2 Dako (Agilent Technologies)
  • 9.3 Roche Holdings
  • 9.4 Qiagen Nv
  • 9.5 Seimens Helthineers
  • 9.6 Takeda Pharmaceuticals
  • 9.7 Myriad Genetics
  • 9.8 Thermo Fisher Scientific
  • 9.9 Tocagen
  • 9.10 Illumina Inc
  • 9.11 Others

10. Future of The Market

Back to Top